These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21614912)

  • 1. Is postoperative CA125 level in patients with epithelial ovarian cancer reliable to guess the optimality of surgery?
    Ghaemmaghami F; Akhavan S
    Eur J Gynaecol Oncol; 2011; 32(2):192-5. PubMed ID: 21614912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer.
    Memarzadeh S; Lee SB; Berek JS; Farias-Eisner R
    Int J Gynecol Cancer; 2003; 13(2):120-4. PubMed ID: 12657110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.
    Arits AH; Stoot JE; Botterweck AA; Roumen FJ; Voogd AC
    Int J Gynecol Cancer; 2008; 18(4):621-8. PubMed ID: 17868339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer.
    Fleming ND; Cass I; Walsh CS; Karlan BY; Li AJ
    Gynecol Oncol; 2011 May; 121(2):249-52. PubMed ID: 21300398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.
    Zwakman N; van de Laar R; Van Gorp T; Zusterzeel PL; Snijders MP; Ferreira I; Massuger LF; Kruitwagen RF
    J Gynecol Oncol; 2017 Jan; 28(1):e7. PubMed ID: 27670261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical study of a CT evaluation model combined with serum CA125 in predicting the treatment of newly diagnosed advanced epithelial ovarian cancer.
    Qin L; Huang H; Chen M; Liang Y; Wang H
    J Ovarian Res; 2018 Jun; 11(1):49. PubMed ID: 29914567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer.
    Plotti F; Scaletta G; Capriglione S; Montera R; Luvero D; Lopez S; Gatti A; De Cicco Nardone C; Terranova C; Angioli R
    Int J Gynecol Cancer; 2017 May; 27(4):696-702. PubMed ID: 28406844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
    Pelissier A; Bonneau C; Chéreau E; de La Motte Rouge T; Fourchotte V; Daraï E; Rouzier R
    Gynecol Oncol; 2014 Dec; 135(3):542-6. PubMed ID: 25223808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
    Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
    Feng LY; Liao SB; Li L
    J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum CA125 levels predict outcome of interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
    Zhang D; Jiang YX; Luo SJ; Zhou R; Jiang QX; Linghu H
    Clin Chim Acta; 2018 Sep; 484():32-35. PubMed ID: 29702068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
    Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
    Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
    Barlow TS; Przybylski M; Schilder JM; Moore DH; Look KY
    Int J Gynecol Cancer; 2006; 16(2):496-500. PubMed ID: 16681717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
    Gilani MM; Karimi Zarchi M; Ghaemmaghami F; Behtash N; Mousavi AS; Ansaripoor S
    Gynecol Oncol; 2007 Jun; 105(3):780-3. PubMed ID: 17433423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection.
    Angioli R; Capriglione S; Aloisi A; Ricciardi R; Scaletta G; Lopez S; Miranda A; Di Pinto A; Terranova C; Plotti F
    Ann Surg Oncol; 2015 Dec; 22(13):4217-23. PubMed ID: 25808099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.
    Karlsen MA; Fagö-Olsen C; Høgdall E; Schnack TH; Christensen IJ; Nedergaard L; Lundvall L; Lydolph MC; Engelholm SA; Høgdall C
    Tumour Biol; 2016 Sep; 37(9):12619-12626. PubMed ID: 27440204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential survival benefit of secondary cytoreductive surgery for recurrent epithelial ovarian, tubal, and peritoneal cancers.
    Goto T; Takano M; Watanabe A; Miyamoto M; Kato M; Hirata J; Sasa H; Furuya K
    Int J Gynecol Cancer; 2011 Feb; 21(2):263-8. PubMed ID: 21270609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
    Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
    Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can primary optimal cytoreduction be predicted in advanced epithelial ovarian cancer preoperatively?
    Mousavi AS; Mazhari MM; Guilani MM; Ghaemmaghami F; Behtash N; Akhavan S
    World J Surg Oncol; 2010 Feb; 8():11. PubMed ID: 20170515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.